<DOCUMENT>
<TYPE>EX-99.4
<SEQUENCE>5
<FILENAME>sinovacexh99_4.txt
<DESCRIPTION>SINOVAC BIOTECH 6K, PRESS RELEASE 8.30.04
<TEXT>






EXHIBIT 99.4
------------


                              SINOVAC BIOTECH LTD.
                              --------------------
      ISSUES CORPORATE UPDATE INCLUDING VACCINE DEVELOPMENT, FINANCING AND
      --------------------------------------------------------------------
                                 GROWTH STRATEGY
                                 ---------------

BEIJING,  August 30, 2004 - Sinovac  Biotech Ltd.  ("Sinovac")  ("the  Company")
(NASD OTC-BB:  SNVBF)  updates  today on many aspects of the Company's  business
activities - past, present, and future.

VACCINES
--------

Sinovac has three  vaccines  that have  completed  all three  phases of clinical
trials - Hepatitis A, Hepatitis A&B combined, and influenza (flu). The Hepatitis
A vaccine,  Healive(TM),  is currently experiencing strong sales growth in China
and  applications  have been filed for its sale in nine other countries to date.
Sinovac's  Hepatitis A&B combined  vaccine,  Bilive(TM),  is expected to receive
approval to commence  sales in China in  September  2004 and to achieve  similar
sales growth to Healive(TM).  The flu vaccine completed clinical trials in April
2004 and a New Drug  Application  has been  filed with the SFDA  (Chinese  FDA).
Approval of Sinovac's flu vaccine is expected in 2005 upon completion of the flu
vaccine  production  line.  Since demand for a safe and effective flu vaccine in
China  greatly  outstrips  supply,  sales  are  expected  to  escalate  rapidly.
Furthermore,  since  individuals  are  vaccinated  against  the flu on an annual
basis, demand will remain high every year.

Sinovac  is the  first  and  currently  the only  company  in the  world to have
commenced  clinical  trials for a vaccine to prevent SARS.  The Company has also
started development for a vaccine targeting avian flu.

SARS Vaccine
------------

November  2003 - Sinovac  announced its  breakthrough  in the creation of a SARS
vaccine and subsequent  plans to commence  clinical  trials for the vaccine upon
the approval by the SFDA  (Chinese  FDA).  Animal tests on safety,  efficacy and
immunology were completed  successfully.  Tests of the vaccine on monkeys showed
it was effective in fighting against SARS infection with no serious side effects
after the animals were exposed to the virus.

January 2004 - Sinovac received approval from the SFDA (Chinese FDA) to commence
clinical  trials for its SARS  vaccine.  Sinovac  jointly  worked with China CDC
(Center of Disease  Control) and the China Medical  Academic College towards the
SARS vaccine.  Clinical  protocols for the testing of Sinovac's  potential  SARS
vaccine were developed in accordance with stringent newly established  worldwide
protocols for the conduct of SARS vaccine  clinical  trials.  The protocols were
developed  with the  cooperation  of the  Chinese  FDA (SFDA)  and world  health
authorities.

February  2004 - Sinovac  received  authorization  from the SFDA to  select  the
China-Japan  Friendship  Hospital  in Beijing  as the  location  to conduct  the
clinical  trial.  Professor  Lin  Jiangtao,  head  of  the  respiratory  Medical
Department of the China-Japan  Friendship Hospital was chosen as the chairperson
of the trial.  Volunteers were screened by the China-Japan  Friendship  Hospital
for the Phase I clinical test.  Sinovac became the only institute to be approved
by the State Drug Administration to conduct clinical trials of a SARS vaccine.

April 2004 - The Chinese  National  Institute for The Control of  Pharmaceutical
and  Biological  Products  (NICPBP)  issued the  testing  report  for  Sinovac's
potential SARS vaccine that stated it had passed all required testing  conducted
by the Chinese State.  The  inactivated  SARS vaccines and control  vaccines are
produced by Sinovac based on "Production  and Testing  Disciplines"  and Quality
Standards filed with the Chinese State Food and Drug Administration.

May 2004 - Phase I human  clinical  trials of SARS  vaccine  commenced  with the
first four  subjects  being  injected with the vaccine on Saturday May 22, 2004.
Throughout  the  months  of June,  July and  August  the  clinical  trials  have
continued  to go  well as more  subjects  have  been  injected  with  low-dosage
vaccine,  placebo,  or high-dosage  vaccine.  Each of the 36 subjects receives 2
injections,  28 days  apart,  of either the  vaccine or the  placebo and will be
observed for 210 days at which time Phase I will be complete.




<PAGE>






August 2004 - All 36 subjects of the Phase I human clinical  trials for its SARS
vaccine have now been vaccinated with either SARS vaccine or placebo.  According
to Professor Lin Jiangtao,  head of the respiratory  Medical Department with the
China-Japan  Friendship  Hospital  in Beijing,  who chairs the trial,  the first
group of 18 who have been inoculated with low-dosage SARS vaccine and the second
group  of 18 who  have  been  inoculated  with  high  dosage  vaccine  have  not
experienced any adverse reaction and are all in good health condition.

December 2004 - Phase I clinical  trials will be complete.  During and after the
Phase I trial,  analysis  will be conducted.  The summary  report of the initial
56-day  observation  period will be sent to the SFDA for its review and the full
210-day report will be completed in early 2005. The first phase of human testing
determines  if the vaccine is safe for the human body.  If the vaccine  receives
SFDA  approval,  then it will  proceed into the Phase II clinical  trial,  which
would include participants from a wider demographic range.

Hepatitis A - Healive(TM)
-------------------------

Sinovac  is  currently  experiencing  strong  sales  growth of its  Hepatitis  A
vaccine,  Healive(TM).  Management of Sinovac is currently  projecting  domestic
Chinese sales of  approximately US $8.5 million for the current year ending 31st
December 2004 - an increase of about three times 2003 sales.

Hepatitis A&B Combined - Bilive(TM)
-----------------------------------

Management  expects to receive  final  approval of its combined  Hepatitis  A&B,
Bilive(TM)  vaccine by the  Chinese  FDA in  September,  and expects to commence
sales of this product by October 2004. SFDA review of all documentation relating
to Bilive(TM) is complete.  The very final part of this approval  process is the
domestic  pricing of the product and that is expected to receive SFDA  clearance
at about US $7 to 8 per dose.  Management  of  Sinovac is  currently  projecting
domestic  Chinese  sales of  approximately  US $1.5 million for the current year
ending 31st December 2004.

Split Flu
---------

Sinovac  completed  clinical  trials  of it split  flu  vaccine  in early  2004.
Management  expects to receive  final  approval  of it Split Flu  vaccine by the
Chinese FDA in 2005 after the split flu production line is built.  500,000 doses
are planned to be sold in 2005 after the completion of the production line and 2
million doses are planned for the following year. After these initial production
levels, production is expected to increase rapidly to meet the escalating demand
of the Chinese population.

Avian Flu (Bird Flu)
--------------------

Sinovac  initiated the Inactivated New Human Influenza  (H5N1) Vaccine  Research
and  Development  Project in March  2004.  Sinovac is working  jointly  with the
Center for Disease  Control of China.  The  research  protocol  has already been
completed and Sinovac has started working towards a vaccine.

Future Vaccine Development
--------------------------

Sinovac is currently  evaluating other vaccine  development  opportunities  that
could offer similar growth potential as the Company's existing product pipeline.

ACQUISITIONS
------------

January 2004 - Sinovac  completed the  acquisition  of Tangshan Yian  Biological
Engineering Co. Ltd. Tangshan Yian operates in the city of Tangshan in China, as
a research and development company specializing in the R & D of various vaccines
including  flu, and  Hepatitis  vaccines.  The R & D operations of Tangshan Yian
complement  Sinovac's  other  operations  in new  and  updated  vaccines  to the
domestic Chinese and international markets.

Sinovac is actively looking for and evaluating potential synergistic acquisition
targets  both in  China  and  internationally.  The  rationale  behind  any such
acquisition  would  be  to  dramatically  increase  corporate  revenues  in  the
short-term,  and to leverage the  acquisitions'  existing  market share to allow




<PAGE>






faster  penetration  of Sinovac's  current  vaccines.  Careful  planning and due
diligence would be conducted before any such acquisition would be completed.

GOVERNMENT FUNDING - RESEARCH AND DEVELOPMENT
---------------------------------------------

To date,  Sinovac has  received a more than $US 2.2 million in research  funding
from the Chinese state government for its inactivated  SARS vaccine  development
program.  It is expected  that  funding of Sinovac's  SARS  vaccine  development
program will continue to be supported by the Chinese  government.  Management of
Sinovac  believes that because of its low-cost  advantage in China,  this amount
funds  significantly  more R & D than the same  research  budget  in the  United
States.

FINANCING
---------

Sinovac  closed a private  placement  offering  in  February  2004.  The private
placement was  oversubscribed and Sinovac raised total proceeds of US$4,750,000.
Each unit of the  placement  consisted  of one share of common stock of Sinovac,
one share purchase  warrant to purchase one additional  share of common stock of
Sinovac at  US$1.50  per  share,  and one  piggyback  warrant  to  purchase  one
additional  share of common stock of Sinovac at US$3.00 per share until November
14, 2005 only if the holder thereof exercises the share purchase warrant.

The  proceeds of the private  placement  are being used for  clinical  trials of
Sinovac's proprietary inactivated SARS vaccine, marketing of the Hepatitis A and
Hepatitis A&B combined vaccines, and construction of state-of-the-art production
facilities for the flu vaccine project.

If the warrants from this financing are fully exercised they would add a further
$18,774,000 to the treasury of Sinovac.

INSTITUTIONAL FINANCING
-----------------------

It is  Sinovac's  intention  to  raise  further  financing  primarily  from  the
institutional  investment community, and also to engage in an investment banking
relationship  to assist the Company  with  financing  its growth.  It is further
anticipated  that such an  investment  bank would assist  Sinovac in  evaluating
potential  Merger & Acquisition  targets and in financing those that offered the
most synergy and made the most strategic sense.

AMEX LISTING
------------

Sinovac's  application  for listing on the  American  Stock  Exchange  (AMEX) is
currently under review.  Sinovac management believes that the Company meets both
the quantitative and qualitative criteria required for listing.

Sinovac currently has shareholders'  equity of approximately US $ 10 million. At
a $3.40 share price, the Company has a $119 million market capitalization. As of
August 2004, Sinovac has over 4,100 shareholders.  Finally,  the market value of
the freely tradable public float is currently about $36 million.  Thus,  Sinovac
management  believes  that it  currently  meets the  quantitative  criteria  for
listing on the American Stock Exchange.

In further evaluating a company's eligibility for listing on AMEX, the following
qualitative  factors are also  considered:  the nature of a company's  business,
market for its products,  reputation of its  management,  historical  record and
pattern of growth, financial integrity,  demonstrated earnings power, and future
outlook.  At this time,  the  Company  believes  that is had  submitted  all the
relevant  documentation  to AMEX in order for the exchange to make an assessment
of whether  Sinovac is eligible for listing.  Furthermore,  management  believes
that the Company has  demonstrated  that it possesses the  qualitative  criteria
that AMEX requires in it listed companies.

If accepted, Sinovac will be among the growing number of biotechnology companies
listed on the American Stock  Exchange.  With a subsequent  listing on the AMEX,
Sinovac   management   feels  that  the  Company   would  benefit  from  greater
accessibility to institutional investment, better share price stability, greater
share liquidity, and increased investor awareness.




<PAGE>






STOCK SPLIT
-----------

The Board of  Directors  has decided  not to move  forward  with the  previously
announced stock split.  It determined  that the proposed  forward stock split of
the  company's  shares of common stock on a basis of two new shares for each old
share was no longer an  advantageous  move for the  company.  This  decision was
based on several factors,  including the fact that Sinovac will benefit from the
above  mentioned  advantages  that  will be gained  by the  Company's  impending
listing  on the  American  Stock  Exchange  as  well as the  preference  of many
institutional investors for stocks that trade above the US $3 level.

DOMESTIC CHINESE MARKET
-----------------------

The Chinese  vaccine  market is quite  unique.  It is  controlled by the Chinese
Centre for  Disease  Control  (China  CDC),  which  serves two  functions:  as a
commercial  sales company and as the governmental  department in  pharmaceutical
sector. As a commercial organization,  China CDC purchases vaccines from vaccine
producers  and  distributes  them  inside  its own  organization.  CDC in  China
consists of many  different  regional  CDCs at different  levels of  government.
Typically,  vaccines are ordered by the provincial  CDC and then  distributed to
the local CDC in each city or county,  and then to the  hospitals.  Sinovac  has
successfully built a sales organization to address this distribution  system. To
date,  the Company  has built up a sales team of 36 people who each  address the
needs of the individual local CDCs around the country.

INTERNATIONAL MARKETS
---------------------

Sinovac is actively  developing its international  market and collaborating with
professional and well-rounded companies in order to accelerate its international
marketing  strategy.  Sinovac  has  submitted  registration  documents  in  nine
countries,   consisting  of  Brazil,  Indonesia,   Mexico,  Malaysia,  Pakistan,
Philippines, Sri Lanka, Thailand, and Vietnam.

"These nine countries  represent  Sinovac's first foreign  applications  for its
affordable  world-class  vaccines.   These  vaccine  registration   applications
represent our initial international markets as we make progress towards sales in
32 targeted countries." stated Sinovac's president, Dr. Wei Dong Yin.

To date,  Sinovac has selected two experienced  marketing and sales companies to
assist  in  marketing   its   products  in   international   markets.   Innopath
International,  a Korean  company,  has extensive  international  vaccine market
experience and a well-organized  worldwide sales network.  Innopath's management
team is assisting Sinovac in developing its international sales. This assistance
includes  marketing strategy  development,  registration in some of the targeted
countries,  and the  establishment of distribution  channels through  Innopath's
existing relationships with vaccine distributors in the international market.

Another  international  sales  agent for  Sinovac is China  National  Medicine &
Health  Products  Import/Export  Corporation  (abbreviated  in China as MEHECO).
MEHECO has a reputation for nurturing diverse  relationships with customers from
more than one hundred countries and regions in the world.

ABOUT SINOVAC BIOTECH LTD.
--------------------------

Sinovac    Biotech   Ltd.    specializes    in   the   research,    development,
commercialization,  and sales of human vaccines for infectious illnesses such as
Hepatitis A and Hepatitis B, influenza and "SARS." Sinovac is one of the leading
emerging  biotechnology  companies in China. Working closely with Chinese public
health  officials,  Sinovac  focuses on  manufacturing  and marketing  human-use
vaccines and related  products,  and currently markets its vaccine for Hepatitis
A.  Sinovac  is the first and  currently  the only  company in the world to have
commenced clinical trials for a vaccine to prevent SARS.

If you would like to receive  regular  updates on Sinovac please send your email
request to info@sinovac.com.
           ----------------

For further  information  please refer to the Company's  filings with the SEC on
EDGAR or refer to Sinovac's website at www.sinovac.com.
                                       ---------------

Contact:   Investor   Relations   at  (888)  888  8312  or  (604)   684-5990  or
info@sinovac.com.
----------------




<PAGE>






THIS NEWS RELEASE MAY INCLUDE  FORWARD-LOOKING  STATEMENTS WITHIN THE MEANING OF
SECTION 27A OF THE UNITED STATES SECURITIES ACT OF 1933, AS AMENDED, AND SECTION
21E OF THE UNITED STATES  SECURITIES AND EXCHANGE ACT OF 1934, AS AMENDED,  WITH
RESPECT  TO  ACHIEVING  CORPORATE  OBJECTIVES,   DEVELOPING  ADDITIONAL  PROJECT
INTERESTS,   SINOVAC'S   ANALYSIS  OF   OPPORTUNITIES  IN  THE  ACQUISITION  AND
DEVELOPMENT  OF VARIOUS  PROJECT  INTERESTS  AND CERTAIN  OTHER  MATTERS.  THESE
STATEMENTS  ARE MADE UNDER THE "SAFE  HARBOR"  PROVISIONS  OF THE UNITED  STATES
PRIVATE  SECURITIES  LITIGATION  REFORM  ACT  OF  1995  AND  INVOLVE  RISKS  AND
UNCERTAINTIES  WHICH COULD CAUSE ACTUAL RESULTS TO DIFFER  MATERIALLY FROM THOSE
IN THE FORWARD-LOOKING STATEMENTS CONTAINED HEREIN.



</TEXT>
</DOCUMENT>
